Status:
RECRUITING
A Trial of SHR-A2102 With Other Antitumor Therapies in Advanced Solid Tumors
Lead Sponsor:
Shanghai Hengrui Pharmaceutical Co., Ltd.
Conditions:
Advanced Solid Tumors
Eligibility:
All Genders
18-70 years
Phase:
PHASE2
Brief Summary
The study is being conducted to evaluate the safety, tolerability and efficacy of SHR-A2102 with other antitumor therapies in advanced solid tumors to explore the reasonable dosage, safety and efficac...
Eligibility Criteria
Inclusion
- The age of signing the informed consent is 18 -70 years, regardless of gender.
- At least one measurable lesion according to RECIST v1.1 criteria.
- The ECOG score is 0 or 1.
- Expected survival ≥12 weeks.
- Good level of organ function.
- Have the ability to give informed consent and to comply with the treatment plan.
- Male subjects whose partners are women of childbearing age and female subjects who are fertile are required to use highly effective contraceptive methods.
Exclusion
- Inadequately treated central nervous system metastases or the presence of uncontrolled or symptomatic active central nervous system metastases.
- Spinal cord compression not cured by surgery and/or radiotherapy.
- Subjects with uncontrolled tumor-related pain.
- Received antitumor therapy within 4 weeks before the start of the study.
- Subjects with severe cardiovascular and cerebrovascular disease.
- History of immunodeficiency, including a positive HIV test.
Key Trial Info
Start Date :
March 28 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2028
Estimated Enrollment :
400 Patients enrolled
Trial Details
Trial ID
NCT06895928
Start Date
March 28 2025
End Date
December 1 2028
Last Update
April 22 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Shanxi Cancer hospital
Taiyuan, Shanxi, China, 030001